The Summary
In a 28-week randomized controlled trial, researchers evaluated oral semaglutide (titrated up to 14 mg daily) alongside lifestyle changes in 116 adults with overweight or obesity and without diabetes. The semaglutide group achieved a 10.47% average weight reduction compared to just 2.4% in the control group. Furthermore, semaglutide significantly decreased liver fat, liver stiffness, and visceral fat, while improving liver enzyme levels (ALT) and key cardiometabolic markers like HbA1c and C-reactive protein, demonstrating comprehensive metabolic benefits.
Why this is interesting
While injectable semaglutide is highly popular, this study highlights the efficacy of the daily oral tablet for non-diabetic individuals. Crucially, it proves that oral semaglutide does not just shed pounds; it actively improves liver health by reducing liver fat and stiffness. For readers struggling with metabolic concerns like fatty liver disease, this offers a convenient, needle-free alternative that targets both body fat and internal organ health simultaneously, bridging the gap between cosmetic changes and true metabolic recovery.